These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 25230018)

  • 1. Intratumoral androgen metabolism and actions in invasive lobular carcinoma of the breast.
    Yoda T; McNamara KM; Miki Y; Takagi M; Rai Y; Ohi Y; Sagara Y; Tamaki K; Hirakawa H; Ishida T; Suzuki T; Ohuchi N; Sasano H
    Cancer Sci; 2014 Nov; 105(11):1503-9. PubMed ID: 25230018
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intratumoral estrogen production and actions in luminal A type invasive lobular and ductal carcinomas.
    Takagi M; Miki Y; Miyashita M; Hata S; Yoda T; Hirakawa H; Sagara Y; Rai Y; Ohi Y; Tamaki K; Ishida T; Suzuki T; Ouchi N; Sasano H
    Breast Cancer Res Treat; 2016 Feb; 156(1):45-55. PubMed ID: 26943913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of cytokines derived from cancer-associated fibroblasts on androgen synthetic enzymes in estrogen receptor-negative breast carcinoma.
    Kikuchi K; McNamara KM; Miki Y; Moon JY; Choi MH; Omata F; Sakurai M; Onodera Y; Rai Y; Ohi Y; Sagara Y; Miyashita M; Ishida T; Ohuchi N; Sasano H
    Breast Cancer Res Treat; 2017 Dec; 166(3):709-723. PubMed ID: 28831645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 5Alpha-reductase type 1 and aromatase in breast carcinoma as regulators of in situ androgen production.
    Suzuki T; Miki Y; Moriya T; Akahira J; Ishida T; Hirakawa H; Yamaguchi Y; Hayashi S; Sasano H
    Int J Cancer; 2007 Jan; 120(2):285-91. PubMed ID: 17066438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor microenvironment in invasive lobular carcinoma: possible therapeutic targets.
    Nakagawa S; Miki Y; Miyashita M; Hata S; Takahashi Y; Rai Y; Sagara Y; Ohi Y; Hirakawa H; Tamaki K; Ishida T; Watanabe M; Suzuki T; Ohuchi N; Sasano H
    Breast Cancer Res Treat; 2016 Jan; 155(1):65-75. PubMed ID: 26715212
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intracrinology of sex steroids in ductal carcinoma in situ (DCIS) of human breast: comparison to invasive ductal carcinoma (IDC) and non-neoplastic breast.
    Miki Y; Suzuki T; Sasano H
    J Steroid Biochem Mol Biol; 2009 Mar; 114(1-2):68-71. PubMed ID: 19444935
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased 5α-reductase type 2 expression in human breast carcinoma following aromatase inhibitor therapy: the correlation with decreased tumor cell proliferation.
    Chanplakorn N; Chanplakorn P; Suzuki T; Ono K; Wang L; Chan MS; Wing L; Yiu CC; Chow LW; Sasano H
    Horm Cancer; 2011 Feb; 2(1):73-81. PubMed ID: 21761341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The prognosis of invasive ductal carcinoma, lobular carcinoma and mixed ductal and lobular carcinoma according to molecular subtypes of the breast.
    Zhao H
    Breast Cancer; 2021 Jan; 28(1):187-195. PubMed ID: 32812198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intratumoral concentration of sex steroids and expression of sex steroid-producing enzymes in ductal carcinoma in situ of human breast.
    Shibuya R; Suzuki T; Miki Y; Yoshida K; Moriya T; Ono K; Akahira J; Ishida T; Hirakawa H; Evans DB; Sasano H
    Endocr Relat Cancer; 2008 Mar; 15(1):113-24. PubMed ID: 18310280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Androgenic pathway in triple negative invasive ductal tumors: its correlation with tumor cell proliferation.
    McNamara KM; Yoda T; Miki Y; Chanplakorn N; Wongwaisayawan S; Incharoen P; Kongdan Y; Wang L; Takagi K; Mayu T; Nakamura Y; Suzuki T; Nemoto N; Miyashita M; Tamaki K; Ishida T; Ohuchi N; Sasano H
    Cancer Sci; 2013 May; 104(5):639-46. PubMed ID: 23373898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Androgen and androgen-metabolizing enzymes in metastasized lymph nodes of breast cancer.
    Shibahara Y; Miki Y; Sakurada C; Uchida K; Hata S; McNamara K; Yoda T; Takagi K; Nakamura Y; Suzuki T; Ishida T; Ohuchi N; Sasano H
    Hum Pathol; 2013 Oct; 44(10):2338-45. PubMed ID: 23953348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential Regulation and Targeting of Estrogen Receptor α Turnover in Invasive Lobular Breast Carcinoma.
    Sreekumar S; Levine KM; Sikora MJ; Chen J; Tasdemir N; Carter D; Dabbs DJ; Meier C; Basudan A; Boone D; McAuliffe PF; Jankowitz RC; Lee AV; Atkinson JM; Oesterreich S
    Endocrinology; 2020 Sep; 161(9):. PubMed ID: 32609836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of DDR1 and DVL1 in invasive ductal and lobular breast carcinoma does not correlate with histological type, grade and hormone receptor status.
    Ameli F; Rose IM; Masir N
    Asian Pac J Cancer Prev; 2015; 16(6):2385-90. PubMed ID: 25824769
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Associations between the standardized uptake value of (18)F-FDG PET/CT and the prognostic factors of invasive lobular carcinoma: in comparison with invasive ductal carcinoma.
    Jung NY; Kim SH; Choi BB; Kim SH; Sung MS
    World J Surg Oncol; 2015 Mar; 13():113. PubMed ID: 25889560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relative effectiveness of adjuvant chemotherapy for invasive lobular compared with invasive ductal carcinoma of the breast.
    Marmor S; Hui JYC; Huang JL; Kizy S; Beckwith H; Blaes AH; Rueth NM; Tuttle TM
    Cancer; 2017 Aug; 123(16):3015-3021. PubMed ID: 28382636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of sarcosine metabolism-related proteins in invasive lobular carcinoma: comparison to invasive ductal carcinoma.
    Cha YJ; Jung WH; Cho NH; Koo JS
    Yonsei Med J; 2015 May; 56(3):598-607. PubMed ID: 25837163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The estrogen receptor coactivator AIB1 is a new putative prognostic biomarker in ER-positive/HER2-negative invasive lobular carcinoma of the breast.
    Narbe U; Sjöström M; Forsare C; Bendahl PO; Alkner S; Leeb-Lundberg LMF; Lövgren K; Rydén L; Ingvar C; Fernö M
    Breast Cancer Res Treat; 2019 Jun; 175(2):305-316. PubMed ID: 30796653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 5alpha-reductases in human breast carcinoma: possible modulator of in situ androgenic actions.
    Suzuki T; Darnel AD; Akahira JI; Ariga N; Ogawa S; Kaneko C; Takeyama J; Moriya T; Sasano H
    J Clin Endocrinol Metab; 2001 May; 86(5):2250-7. PubMed ID: 11344235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biologic markers in axillary node-negative breast cancer: differential expression in invasive ductal carcinoma versus invasive lobular carcinoma.
    Gonzalez-Angulo AM; Sahin A; Krishnamurthy S; Yang Y; Kau SW; Hortobagyi GN; Cristofanilli M
    Clin Breast Cancer; 2006 Dec; 7(5):396-400. PubMed ID: 17239264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Triple-negative breast lobular carcinoma: a luminal androgen receptor carcinoma with specific ESRRA mutations.
    Bergeron A; MacGrogan G; Bertaut A; Ladoire S; Arveux P; Desmoulins I; Bonnefoi H; Loustalot C; Auriol S; Beltjens F; Degrolard-Courcet E; Charon-Barra C; Richard C; Boidot R; Arnould L
    Mod Pathol; 2021 Jul; 34(7):1282-1296. PubMed ID: 33753865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.